Our group is focused on the development of novel diagnostic and therapeutic approaches for the treatment of patients with genitourinary (GU) cancers, which includes prostate, bladder, and kidney cancer among others. Our approach involves the retrospective development of candidate prognostic and predictive biomarkers utilizing a comprehensive clinical database and specimen biorepository along with prospective validation of these biomarkers in clinical trials. By combining mechanism-based molecular markers with novel therapeutics, our ultimate goal is to ultimately enhance the care of patients with genitourinary malignancies by maximizing the likelihood of benefit from treatment while minimizing the risk of adverse events.
1425 Madison Avenue,1st Floor
New York, NY 10029